Morphocell Technologies announces completion of US$40 Million Series A financing

Ontario Industry UpdatesOBIO News
Written By Arsheen Kaur

Morphocell Technologies Inc., a Montreal-based biotechnology company in the cell therapy space, recently announced the closure of a US$40 million Series A funding round. The funding is set to fuel the company’s groundbreaking journey towards a first-in-human clinical trial of the first cell therapy issued from its tissue engineering platform, aimed at transforming liver disease treatment globally.

Morphocell Technologies is an alumnus of our CAAP® program and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Voyce, Hamilton Health Sciences and OBIO® Showcase Breakthrough in Patient Care Through Language Access Technology
Next

Rocket Doctor selected for the inaugural cohort of the Google for Startups Accelerator